
Lilly To Release Data Targeting Key Cancer Pathways At AACR 2014
Eli Lilly will present early-stage data regarding cancer therapies at AACR 2014.
Data from bemaciclib as a potential treatment for metastatic breast cancer, has been accepted as a presentation at AACR's Clinical Trials Symposium and will be featured in an AACR-sponsored press conference.
Lilly's B-Raf inhibitor LY3009120 will be displayed at AACR's New Drugs on the Horizon special session where there will be discussions regarding new anti-cancer compounds that target key pathways. There will also be an oral presentation on Lilly's c-MET kinase inhibitor, LY2801653.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.